Breaking News Instant updates and real-time market news.

ACRS

Aclaris Therapeutics

$28.04

0.31 (1.12%)

07:35
11/29/16
11/29
07:35
11/29/16
07:35

Aclaris Therapeutics initiated with an Outperform at Leerink

Leerink analyst Seamus Fernandez started Aclaris Therapeutics with an Outperform rating and $54 price target, saying he assumes its A-101 is approved and successful for seborrheic keratosis, with a 50% probability of success for A-101 for common warts.

  • 07

    Dec

ACRS Aclaris Therapeutics
$28.04

0.31 (1.12%)

09/19/16
JEFF
09/19/16
NO CHANGE
Target $31
JEFF
Buy
Aclaris Therapeutics price target raised to $31 from $23 at Jefferies
Jefferies analyst David Steinberg raised his price target for Aclaris Therapeutics to $31 saying he's "increasingly optimistic" about the outlook for a second indication for A-101 after the company last week released additional information on the common wart Phase 2 study. The sustainability of the franchise could be further bolstered by new patents, Steinberg tells investors in a research note. He raised his peak sales estimate for A-101 to $250M from $75M and keeps a Buy rating on Aclaris.
09/30/16
JMPS
09/30/16
INITIATION
JMPS
Outperform
Aclaris Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Donald Ellis started coverage of Aclaris with a $34 price target.
11/16/16
JEFF
11/16/16
NO CHANGE
Target $32
JEFF
Buy
Aclaris Therapeutics price target raised to $32 from $29 at Jefferies
Jefferies analyst David Steinberg raised his price target for Aclaris Therapeutics to $32 saying A-101 for seborrheic keratosis looks approvable following yesterday's positive Phase III data. The analyst believes the data readout is a "significant de-risking event" for Aclaris and sees potential peak sales of $500M-plus. He adds that the company fits with his firm's M&A thesis. Steinberg reiterates a Buy rating on Aclaris.
11/16/16
JMPS
11/16/16
NO CHANGE
JMPS
Aclaris Therapeutics price target raised to $39 from $34 at JMP Securities
JMP Securities analyst Donald Ellis says that data for Aclaris' A-101 drug was "highly positive" and he thinks that the drug is "substantially derisked." The analyst thinks that there is an 80% chance of the drug being approved, and he keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

NEPT

Neptune Technologies

$2.91

-0.11 (-3.64%)

08:07
01/19/18
01/19
08:07
01/19/18
08:07
Hot Stocks
Neptune Technologies announces research agreement »

Neptune Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMLP

Golar LNG Partners

$22.41

-0.5 (-2.18%)

08:06
01/19/18
01/19
08:06
01/19/18
08:06
Hot Stocks
Golar LNG Partners secures new long-term FSRU contract »

Golar LNG Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

08:06
01/19/18
01/19
08:06
01/19/18
08:06
Hot Stocks
Schlumberger to exit marine and land seismic acquisition market »

Earlier, Schlumberger CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

KSU

Kansas City Southern

$111.50

0.69 (0.62%)

08:05
01/19/18
01/19
08:05
01/19/18
08:05
Earnings
Kansas City Southern reports Q4 EPS $1.38 ex-items, consensus $1.37 »

Reports Q4 revenue $660M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

AVGR

Avinger

$0.21

0.0056 (2.79%)

08:05
01/19/18
01/19
08:05
01/19/18
08:05
Hot Stocks
Avinger granted continued listing decision from Nasdaq »

Avinger announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSRR

Sierra Bancorp

$27.66

-0.31 (-1.11%)

08:03
01/19/18
01/19
08:03
01/19/18
08:03
Hot Stocks
Sierra Bancorp increases dividend 14% to 16c »

Sierra Bancorp, parent of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALBO

Albireo Pharma

$29.47

1.46 (5.21%)

08:03
01/19/18
01/19
08:03
01/19/18
08:03
Hot Stocks
Albireo Pharma to receive over $55M in nondilutive cash payments »

Albireo Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMAN

eMagin

08:03
01/19/18
01/19
08:03
01/19/18
08:03
Earnings
eMagin reports preliminary Q4 revenue $6.2M-$6.4M, consensus $5.77M »

Compared to the third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUN

Huntsman

$34.28

0.12 (0.35%)

08:03
01/19/18
01/19
08:03
01/19/18
08:03
Initiation
Huntsman initiated  »

Huntsman initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZAYO

Zayo Group

$35.63

-0.95 (-2.60%)

08:02
01/19/18
01/19
08:02
01/19/18
08:02
Hot Stocks
Zayo Group acquires Optic Zoo Networks for C$31M »

Zayo Group Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

MA

MasterCard

$165.48

1.16 (0.71%)

08:02
01/19/18
01/19
08:02
01/19/18
08:02
Recommendations
MasterCard analyst commentary  »

MasterCard price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

QCOM

Qualcomm

$68.05

0.03 (0.04%)

, NXPI

NXP Semiconductors

$120.00

0.66 (0.55%)

08:01
01/19/18
01/19
08:01
01/19/18
08:01
Hot Stocks
Elliott: Qualcomm can deliver value at prices for NXP higher than $135/share »

Elliott Advisors, which…

QCOM

Qualcomm

$68.05

0.03 (0.04%)

NXPI

NXP Semiconductors

$120.00

0.66 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TEAM

Atlassian

$55.60

0.73 (1.33%)

08:01
01/19/18
01/19
08:01
01/19/18
08:01
Recommendations
Atlassian analyst commentary  »

Atlassian weakness would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

08:00
01/19/18
01/19
08:00
01/19/18
08:00
Recommendations
Amazon.com analyst commentary  »

Amazon doesn't look…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 01

    Feb

  • 18

    Mar

NEM

Newmont Mining

$39.24

-0.21 (-0.53%)

08:00
01/19/18
01/19
08:00
01/19/18
08:00
Options
Newmont Mining put buyer realizes 16% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CS

Credit Suisse

$18.93

0.21 (1.12%)

07:59
01/19/18
01/19
07:59
01/19/18
07:59
Periodicals
Credit Suisse's top China dealmaker set to leave, Bloomberg reports »

Mervyn Chow, Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

LSXMA

Liberty SiriusXM

$40.83

0.29 (0.72%)

07:59
01/19/18
01/19
07:59
01/19/18
07:59
Initiation
Liberty SiriusXM initiated  »

Liberty SiriusXM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$41.30

0.1 (0.24%)

, BSFT

BroadSoft

$55.00

0.05 (0.09%)

07:57
01/19/18
01/19
07:57
01/19/18
07:57
Conference/Events
BroadSoft to host special shareholder meeting »

Special Shareholder…

CSCO

Cisco

$41.30

0.1 (0.24%)

BSFT

BroadSoft

$55.00

0.05 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBT

BB&T

$54.14

0.86 (1.61%)

07:55
01/19/18
01/19
07:55
01/19/18
07:55
Recommendations
BB&T analyst commentary  »

BB&T price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$92.97

0.8 (0.87%)

07:54
01/19/18
01/19
07:54
01/19/18
07:54
Periodicals
Turner, Warner Bros. to launch FilmStruck internationally, Variety reports »

Turner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANAB

AnaptysBio

$110.45

-1.11 (-0.99%)

07:54
01/19/18
01/19
07:54
01/19/18
07:54
Recommendations
AnaptysBio analyst commentary  »

AnaptysBio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$99.86

-0.9 (-0.89%)

07:53
01/19/18
01/19
07:53
01/19/18
07:53
Recommendations
American Express analyst commentary  »

Credit Suisse keeps…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANF

Abercrombie & Fitch

$18.95

0.09 (0.48%)

07:50
01/19/18
01/19
07:50
01/19/18
07:50
Upgrade
Abercrombie & Fitch rating change  »

Abercrombie & Fitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$232.12

0.75 (0.32%)

07:49
01/19/18
01/19
07:49
01/19/18
07:49
Initiation
Becton Dickinson initiated  »

Becton Dickinson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

TSM

TSMC

$44.57

1.44 (3.34%)

07:48
01/19/18
01/19
07:48
01/19/18
07:48
Periodicals
TSMC sees revenue growth of 10%-15% in 2018, DigiTimes reports »

Taiwan Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.